Page 26 - 2019_12-Haematologica-web

R.A.L. de Groen et al.
Table 1. (A, B) Overview of reported frequencies of MYD88(L265P) in B-cell neoplasms according to the 2016 World Health Organization classification of lymphoid neoplasms110 (A) and other mature B-cell neoplasms with specific disease locations (B).
1A
MatureB-cellneoplasms
Chronic lymphocytic leukemia/small lymphocytic lymphoma
Monoclonal B-cell lymphocytosis B-cell prolymphocytic leukemia Splenic marginal zone lymphoma Hairy cell leukemia
Splenic B-cell lymphoma/leukemia, unclassifiable Lymphoplasmacytic lymphoma
Non-IgM lymphoplasmacytic lymphoma Waldenström macroglobulinemia
Monoclonal gammopathy of undetermined
significance, IgM
Monoclonal gammopathy of undetermined significance, IgG/A
Plasma cell myeloma
Solitary plasmacytoma of bone
Extraosseous plasmacytoma
Monoclonal immunoglobulin deposition diseases
Extranodal marginal zone lymphoma of
mucosa-associated lymphoid tissue (MALT lymphoma) Nodal marginal zone lymphoma
Follicular lymphoma
Pediatric-type follicular lymphoma
Large B-cell lymphoma with IRF4 rearrangement
Primary cutaneous follicle center lymphoma
Mantle cell lymphoma
Diffuse large B-cell lymphoma (DLBCL), NOS Germinal center B-cell type
Activated B-cell type
T-cell/histiocyte-rich large B-cell lymphoma Primary DLBCL of the central nervous system Primary cutaneous DLBCL, leg type
EBV+ DLBCL, NOS
EBV+ mucocutaneous ulcer
DLBCL associated with chronic inflammation
Lymphomatoid granulomatosis
Primary mediastinal (thymic) large B-cell lymphoma
Intravascular large B-cell lymphoma
ALK+ Large B-cell lymphoma
Plasmablastic lymphoma
Primary effusion lymphoma HHV8+ DLBCL, NOS
Burkitt lymphoma
Burkitt-like lymphoma with 11q aberration
High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements
High-grade B-cell lymphoma, NOS
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma
MYD88(L265P) MYD88(L265P) Total
Range
0–25%
N.A.
0–50% 0–8% N.A. 0–100% 42 – 100% 57 – 100% 0–100%
N.A.
0–30%
0–13%
0–71% 0–50% N.A.
N.A. 0–50%
0–71% 0–57% 8–61%
33 – 100% 40–75% 0–22% N.A.
N.A. N.A.
0–2% N.A.
Number References of studies
41 18, 22-24, 28, 38-53
2 53, 54
19 18, 23, 29, 55, 56 5 22, 30, 57-59 1 60
16 18, 22-30
7 18, 23, 31, 33, 61 34 18, 22, 23, 31-37
13 18, 22, 23, 62
3 18, 22, 23, 34
14 18, 22, 23, 30, 43,
63, 106, 107
9 18, 22, 23, 64, 65
9 18, 22, 23, 66 10 18, 22, 23, 67, 68
2 69, 70
3 71-73 6 30, 43, 74
43 3, 18, 22, 23, 67, 75-84, 113 21 3, 22, 23, 79-81, 85
21 3, 22, 23, 79-81, 85
21 18, 22, 23, 86-88,96 9 22, 71, 89-91
4 22, 83, 92
1 93
3 2,3,94 1 95
2 2, 74 1 83
prevalence
2.5%
0% Unknown* 7.0% 1.1% 16.7% 85.5% 55.0% 85.3% 52.7%
0%
1.5%
Unknown* Unknown* Unknown* 3.9%
10.3% 1.9% 0% Unknown* 0% 6.7% 15.6%
5.3% 22.9%
Unknown* 60.8% 62.2% 4.4%
incidence sequenced
221 8773
0 75
59 840 1 89 1 6 337 394 33 60 1888 2213 301 571
0 41
3 205
15 383
16 156 5 264 0 27
0 60
2 30
853 5457 81 1520 492 2151
382 628 138 222 4 90
0% 0 14 Unknown*
Unknown*
0% 0 68
44.0% 11 25 Unknown*
Unknown*
Unknown*
Unknown*
1.5% 1 67
Unknown*
11.1% 1 9
Unknown* Unknown*
2340
haematologica | 2019; 104(12)